Results 221 to 230 of about 178,774 (332)

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, EarlyView.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

Predicting bevacizumab efficacy: the emerging role of ACTL6B in colorectal cancer. [PDF]

J Gastrointest Oncol
Weng X, Zhu J, Zhou X.
europepmc   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source

Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China. [PDF]

Front Immunol
Li Z, He J, Ma K.
europepmc   +1 more source

High levels of serum cholesterol increase the risk of developing vessel co‐opting tumors in colorectal cancer liver metastases

The FEBS Journal, EarlyView.
High serum cholesterol is linked to colorectal cancer liver metastases (CRCLM) subtypes with poor survival (replacement pattern). Levels of cholesterol under 4 mmol·L−1 correlated with better survival and a desmoplastic pattern subtype. Furthermore, in vivo PCSK9 inhibitor evolocumab, which lowers cholesterol, reduced liver metastases.
Amatzia Gantz, Audrey Kapelanski‐Lamoureux, Miran Rada, Lucyna Krzywon, Migmar Tsamchoe, Anastasia Tsatoumas, Stephanie K. Petrillo, Nabil G. Seidah, Anthoula Lazaris, Peter Metrakos   +9 more
wiley   +1 more source

A network meta-analysis of first-line treatment options for patients with Child-Pugh class B functional hepatocellular carcinoma: comparison of efficacy and safety. [PDF]

Front Pharmacol
Zhang YX, Wu JY, Wu JY, Zeng ZX, Pan RJ, Ou XY, Li YN, Yan ML.   +7 more
europepmc   +1 more source

TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis

Youwen Zhu, Kun Liu, Hong Zhu
openalex   +1 more source

129TiP: A single arm phase II study evaluating intracranial efficacy of sacituzumab govitecan (SG) with bevacizumab (BEV) in patients (pts) with active, asymptomatic brain metastases (BM) from non-small cell lung cancer (NSCLC) [PDF]

L. Hendriks, Frederike Bensch, Willemijn S.M.E. Theelen, Monique M. Anten, Martijn Broen, L. Jacobi-Postma, Hester Tamminga, Bianca van den Bosch, Sander Croes, Robin M.J.M. van Geel   +9 more
openalex   +1 more source

Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer [PDF]

, 2017
Mitsuharu Earashi, K. Matsui, Keisuke Maeda, Wataru Fukushima, K. Shimada, Tetsuro Shimizu, Zensei Nozaki, Yasuko Tanada, K. Oyama, Takuya Nagata, Atsushi Tsuneda, Akira Yoshikawa, Toru Yoshida, K. Kiyohara, Kenneth K. Iwata, T Ii   +15 more
openalex   +1 more source

Efficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis

Hepatology Research, EarlyView.
ABSTRACT Background Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...
Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa   +11 more
wiley   +1 more source